DAWN - Day One Biopharmaceuticals Price-to-Projected Revenue Ratio

The future P/S metric correlates with the use of automated drug synthesis and development algorithms, with the parameter reaching 14.00. Day One is currently scaling sales of its first approved drug while expanding its hospital network and molecule portfolio. A noble mission to save children and generous stock options help the company attract leading scientists and clinicians.

Day One Biopharmaceuticals, Inc. - DAWN Projected Price to Revenue (period 08/01/2024 - 05/09/2026)

Comprehensive metric breakdowns and analytics for Day One Biopharmaceuticals Inc (DAWN)

- market price and analyst price targets:

Price Chart Day One Biopharmaceuticals|DAWN - Price Target Chart

- market capitalization statistics:

Market Value Day One Biopharmaceuticals Inc|DAWN - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Day One Biopharmaceuticals|DAWN - Book Value of Business|Market Cap to Net Assets Ratio dayonebio.com|DAWN - Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio Day One|DAWN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Day One|DAWN - Company Cumulative Indebtedness|Debts to Book Capitalization Day One Biopharmaceuticals Inc|DAWN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Day One Biopharmaceuticals|Quick Liquidity dayonebio.com

- financial results and valuation multiples details:

DAWN - Final Profit|Projected Future Earnings Day One|DAWN - P/E Multiple|Future Price to Earnings Day One Bio|DAWN - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Day One Biopharmaceuticals Inc|DAWN - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Day One Biopharmaceuticals|DAWN - Earnings per share for the last 12 months|Quarterly EPS earnings growth dayonebio.com|DAWN - Earnings growth in current year|Expected earnings per share growth for next year Day One

- revenue and sales proceeds data:

DAWN - Company Total Revenue|Company Future Sales Volume Day One Biopharmaceuticals|DAWN - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Day One Biopharmaceuticals Inc

General company analysis:Day One Biopharmaceuticals DAWN

Day One (DAWN) holds a monopoly position in the treatment of pediatric glioma, making revenue the key driver of value. This indicator compares current market capitalization with projected income, eliminating time gaps between quarterly reports. By analyzing changes in the forward P/S ratio, investors can see the immediate market reaction to news regarding Ojemda sales. This allows for an objective assessment of whether the market is overpaying for the uniqueness of this niche asset.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Monopar Corp|INBX: Forward P/S Multiple|Projected Price to Revenue I-Mab Biopharma IMAB|Forward Price-to-Revenue Multiple FENC|Market Cap to Future Revenue Ratio Heron Therapeutics Inc HRTX|Forward Price-to-Revenue Multiple NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Forward Price to Sales|Corbus Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRDF (Cardiff Oncology Inc.)|BeyondSpring - Forward P/S Multiple|Forward Price to Sales BCAB (BioAtla, Inc.)|LIXT: Forward P/S Multiple|Market Cap to Future Revenue Ratio Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Projected Revenue Ratio Cellectar Biosciences|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|CYCC: Forward P/S Multiple|Market Cap to Projected Revenue GTHX|KRON (Kronos Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Kintara Pharma|Forward Price-to-Revenue Multiple ONCT (Oncternal Therapeutics)|PRTG - Market Cap to Future Revenue Ratio